
About


Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy

CTA Update: Domestic Reporting Companies Exempt from Reporting to FinCEN

Federal Circuit: Reissue Patents Get PTE Based on the Original Patent’s Issue Date

Federal Circuit Denies Teva’s Request for En Banc Rehearing in Orange Book Patent Dispute

Corporate Transparency Act Requirements Are Back: March 21, 2025 Deadline Looms

Biosimilars at the Crossroads: A $234 Billion Opportunity or a Missed Chance for Healthcare Savings?

How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated January 13, 2025

Latest Update: Corporate Transparency Act Halted Again
